Rhythm Pharmaceuticals Analyst Ratings
Canaccord Genuity Maintains Buy on Rhythm Pharmaceuticals, Lowers Price Target to $79
Maintaining Buy Rating on Rhythm Pharmaceuticals: Positive Outlook Amidst Growth and Upcoming Catalysts
BofA Downgrades Rhythm Pharmaceuticals to Neutral From Buy, Adjusts Price Target to $42 From $49
Steady Performance and Promising European Growth Justify Buy Rating for Rhythm Pharmaceuticals
B of A Securities Downgrades Rhythm Pharmaceuticals to Neutral, Lowers Price Target to $42
Needham: Maintaining the Rhythm Pharmaceuticals (RYTM.US) rating, adjusted from buy to buy rating, and the target price was adjusted from $50.00 to $46.00.
Rhythm Pharmaceuticals Analyst Ratings
Analysts Conflicted on These Healthcare Names: Gilead Sciences (GILD), Rhythm Pharmaceuticals (RYTM) and Dexcom (DXCM)
Needham: Reiterates Rhythm Pharmaceuticals (RYTM.US) rating and adjusted from buy to buy rating, target price of $50.00.
Rhythm Pharmaceuticals Analyst Ratings
Needham Reiterates Buy on Rhythm Pharmaceuticals, Maintains $50 Price Target
Wells Fargo: Maintaining the Rhythm Pharmaceuticals (RYTM.US) rating, adjusted from an increase in holdings to an increase rating, and the target price was adjusted from $53.00 to $52.00.
Rhythm Pharmaceuticals Analyst Ratings
Wells Fargo Maintains Overweight on Rhythm Pharmaceuticals, Lowers Price Target to $52
Wells Fargo Remains a Buy on Rhythm Pharmaceuticals (RYTM)
Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (JNJ), Amylyx Pharmaceuticals Inc (AMLX) and Rhythm Pharmaceuticals (RYTM)
Buy Rating Justified by Rhythm Pharmaceuticals' Strong Market Entry and Promising Pipeline
Needham: Reiterates Rhythm Pharmaceuticals (RYTM.US) rating and adjusted from buy to buy rating, target price of $50.00.
Rhythm Pharmaceuticals Analyst Ratings